Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma

Article English OPEN
Maybury, B ; Cook, G ; Pratt, G ; Yong, K ; Ramasamy, K (2016)
  • Publisher: Elsevier
  • Subject: Multiple myeloma, Stem cell transplantation, Conditioning, Immunotherapy, Minimal residual disease

Consolidation with high-dose chemotherapy and autologous stem cell transplantation (ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma, based on randomized trials showing improved progression-free survival with autologous transplantation after combination chemotherapy induction. These trials were performed before novel agents were introduced; subsequently, combinations of immunomodulatory drugs and proteasome inhibitors as induction therapy have significantly improved rates and depth of response. Ongoing randomized trials are testing whether conventional autologous transplantation continues to improve responses after novel agent induction. Although these results are awaited, it is important to review strategies for improving outcomes after ASCT. Conditioning before ASCT with higher doses of melphalan and combinations of melphalan with other agents, including radiopharmaceuticals, has been explored. Tandem ASCT, consolidation, and maintenance therapy after ASCT have been investigated in phase III trials. Experimental cellular therapies using ex vivo–primed dendritic cells, ex vivo–expanded autologous lymphocytes, Killer Immunoglobulin Receptor (KIR)-mismatched allogeneic natural killer cells, and genetically modified T cells to augment ASCT are also in phase I trials. This review summarizes these strategies and highlights the importance of exploring strategies to augment ASCT, even in the era of novel agent induction.
  • References (121)
    121 references, page 1 of 13

    Abidi, M.H., Agarwal, R., Tageja, N., Ayash, L., Deol, A., Al-Kadhimi, Z., Abrams, J., Cronin, S., Ventimiglia, M., Lum, L., Ratanatharathorn, V., Zonder, J., Uberti, J. (2013) A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function. Biology of Blood and Marrow Transplantation, 19, 56-61.

    Alexanian, R., Weber, D., Dimopoulos, M., Delasalle, K. & Smith, T.L. (2000) Randomized trial of alphainterferon or dexamethasone as maintenance treatment for multiple myeloma. American Journal of Hematology, 65, 204-209.

    Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91- 97.

    Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B., Bataille, R. & InterGroupe Francophone du Myelome. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. The New England Journal of Medicine, 349, 2495-2502.

    Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Yakoub Agha, I., Bourhis, J.H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., Avet-Loiseau, H., Moreau, P., Facon, T. & Inter-Groupe Francophone du Myelome (IFM). (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 108, 3289-3294.

    Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A.M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet-Loiseau, H., Harousseau, J.L. & IFM Investigators. (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. The New England Journal of Medicine, 366, 1782-1791.

    Attal, M., Lauwers-Cances, V., Hulin, C., Facon, T., Caillot, D., Escoffre, M., Arnulf, B., MACRO, M., Belhadj, K., Garderet, L., Roussel, M., Mathiot, C., Avet-Loiseau, H., Munshi, N.C., Richardson, P.G., Anderson, K.C., Harousseau, j.L. & Moreau, P. (2015) Autologous transplantation for multiple myeloma in the era of new drugs: A phase III study of the intergroupe francophone du myelome (IFM/DFCI 2009 trial). Blood (ASH Annual Meeting Abstracts), 126, 391.

    Badros, A.Z., Kocoglu, M.H., Ma, N., Rapoport, A.P., Lederer, E., Philip, S., Lesho, P., Dell, C., Hardy, N.M., Yared, J., Goloubeva, O. & Singh, Z. (2015) A phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with Relapsed/Refractory multiple myeloma (RRMM). Blood (ASH Annual Meeting Abstracts), 126, 506.

    Baldini, L., Radaelli, F., Chiorboli, O., Fumagalli, S., Cro, L., Segala, M., Cesana, B.M., Polli, E.E. & Maiolo, A.T. (1991) No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. Cancer, 68, 62-67.

    Ballestrero, A., Ferrando, F., Miglino, M., Clavio, M., Gonella, R., Garuti, A., Grasso, R., Ghio, R., Balleari, E., Gobbi, M. & Patrone, F. (2002) Three-step highdose sequential chemotherapy in patients with newly diagnosed multiple myeloma. European Journal of Haematology, 68, 101-106.

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark